DOP Session 7

  • 17:20-18:20 Digital Oral Presentation Session 7 - Novel therapies
    Room: Strauss 3, Ground Floor, Congress Centre
    Chairs:
    Marc Ferrante, Leuven, Belgium
    Peter Irving, London, United Kingdom
      17:20-17:26 DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patients
    R. Atreya1, T. Kühbacher2, 3, H. Schmitt1, S. Hirschmann1, M.J. Waldner1, O. Drvarov2, S. Fischer1, M. Vetter1, B. Weigmann1, A. Turowska4, T. Mühl4, U. Homburg4, J. Renz4, M. Vieth5, H. Garn6, H. Renz6, M.F. Neurath1
    1. Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany
    2. Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany
    3. Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany
    4. Sterna biologicals GmbH Co & KG, Marburg, Germany
    5. Institute of Pathology, Bayreuth, Germany
    6. Philipps University Marburg, Marburg, Germany
      17:26-17:32 DOP056: Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn’s Disease who had lost response to anti-TNFα agents : A multicentre, open-label, Phase 1/2 study
    K. Matsuoka1, M. Naganuma2, S. Tanida3, K. Kitamura4, T. Matsui5, M. Arai6, M. Fujiya7, N. Horiki8, H. Nebiki9, F. Kinjo10, T. Miyazaki11, T. Matsumoto12, M. Esaki13, K. Mitsuyama14, M. Saruta15, A. Ido16, S. Hojo17, O. Takenaka17, K. Oketani18, T. Imai19, H. Tsubouchi20, T. Hibi21, T. Kanai2
    1. Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan
    2. Keio University School of Medicine, Internal Medicine, Gastroenterology and Hepatology, Tokyo, Japan
    3. Nagoya City University Graduate School of Medical Sciences, Gastroenterology and Metabolism, Aichi, Japan
    4. Kanazawa University Hospital, Gastroenterology, Ishikawa, Japan
    5. Fukuoka University Chikushi Hospital, Gastroenterology, Fukuoka, Japan
    6. Chiba University Hospital, Gastroenterology, Chiba, Japan
    7. Asahikawa Medical University, Gastroenterology and Hematology/Oncology, Hokkaido, Japan
    8. Mie University Hospital, Endoscopy, Mie, Japan
    9. Osaka City General Hospital, Gastroenterology, Osaka, Japan
    10. Urasoe General Hospital, Center for Gastroenterolog, Okinawa, Japan
    11. Hyogo College of Medicine, Inflammatory Bowel Disease, Hyogo, Japan
    12. Iwate Medical University, Internal Medicine, School of Medicine,
    Gastroenterology, Iwate, Japan
    13. Kyushu University Graduate School of Medical Sciences, Medicine and Clinical Science, Fukuoka, Japan
    14. Kurume University School of Medicine, Inflammatory Bowel Disease Center, Fukuoka, Japan
    15. The Jikei University School of Medicine, Gastroenterology and Hepatology,
    Tokyo, Japan
    16. Kagoshima University Graduate School of Medicine and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima, Japan
    17. Eisai. Co., Ltd., Tokyo, Japan
    18. EA Pharma Co., Ltd., Tokyo, Japan
    19. KAN Research Institute, Hyogo, Japan
    20. Kagoshima City Hospital, Kagoshima, Japan
    21. Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

      17:32-17:38 DOP057: ECCO-EBMT joint paper: Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s Disease: Summary of the ECCO-EBMT joint review
    J. Snowden1, J. Panes2, T. Alexander3, M. Allez4, S. Ardizzone5, D. Dierickx6, J. Finke7, P. Hasselblatt7, C. Hawkey8, M. Kazmi9, J. Lindsay10, F. Onida11, A. Salas2, R. Saccardi12, S. Vermeire13, M. Rovira14, E. Ricart2
    1. Sheffield Teaching Hospitals NHS Foundation Trust, Haematology, Sheffield, United Kingdom

    2. Hospital Clínic, IDIBAPS, CIBERehd, Gastroenterology, Barcelona, Spain
    3. Charité – University Medicine Berlin, 1. Department of Rheumatology and
    Clinical Immunology, Berlin, Germany
    4. Hôpital Saint Louis, APHP, INSERM U1160, Paris Diderot, Sorbonne Paris-Cité University, Gastroenterology, Paris, France
    5. DIBIC - ASST Fatebenefratelli Sacco - University of Milan, Gastroenterology,
    Milan, Italy
    6. University Hospitals Leuven, Haematology, Leuvan, Belgium
    7. Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Medicine II, Freiburg, Germany
    8. University of Nottingham, Nottingham Digestive Diseases Centre, Nottingham, United Kingdom
    9. Guys & St Thomas’ NHS Foundation Trust, Haematology, London, United Kingdom
    10. The Royal London Hospital, Barts Health NHS Trust & Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Gastroenterology, London, United Kingdom
    11. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Hematology-BMT Center, Milan, United Kingdom
    12. Careggi University Hospital, Department of Haematology, Firenze, Italy
    13. University hospitals Leuven, Department of Gastroenterology, Leuven, Belgium
    14. IDIBAPS, Hospital Clinic, BMT Unit, Hematology Department & Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain 
      17:38-17:44 DOP058: Combined stem cells and anticytokine therapy contributes to a more pronounced decrease in the degree of inflammation of the intestinal mucosa in Crohn's Disease
    N. Fadeeva
    1, O. Knyazev1A. Kagramanova1, E. Dobroluybova1, I. Donchenko1, S. Khomeriki2, A. Babayan1, A. Lishchinskaya3, A. Konoplyannikov4
    1. Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation
    2. Moscow Clinical Research Center, Department of Pathology, Moscow, Russian Federation
    3. Moscow Clinical Research Center, Moscow, Russian Federation
    4. Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation
      17:44-17:50 DOP059: Combined anticytokine and local mesenchymal stem cells therapy promotes longer healing of simple fistulas in patients with Crohn's Disease
    N.
    Belyakov1, O. Knyazev1, N. Fadeeva1, N. Orlova2, A. Konoplyannikov3, A. Parfenov1, A. Kagramanova1
    1. Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation
    2. Moscow Clinical Research Center, Department of Radiology, Moscow, Russian Federation
    3. Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation
      17:50-17:56 DOP060: Human amnion epithelial cells and their conditioned media reduces intestinal inflammation and fibrosis in a murine model of chronic colitis
    N. Kuk
    1, 2, J. Correia1, 2, M. Alhomrani1, 2, 3, R. Lim3, W. Sievert1, 2, A. Hodge1, 2, G. Moore1, 2
    1. Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
    2. Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, Australia
    3. Hudson Institute for Medical Research, Melbourne, Australia
       17:56-18:02 DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of Acute Colitis
    N. Kuk
    1, 2, J. Correia1, 2, M. Alhomrani1, 2, 3, R. Lim3, W. Sievert1, 2, A. Hodge1, 2, G. Moore1, 2
    1. Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
    2. Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, Australia
    3. Hudson Institute for Medical Research, Melbourne, Australia
      18:02-18:08 DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s Disease: Endoscopic effects of induction therapy
    G.R. D´Haens
    1 , K. Gorelick2, Y. Wang3, F. Cataldi3, W.J. Sandborn4
    1. Academic Medical Centre, Amsterdam, Netherlands
    2. Zymo Consulting Group, Newtown Square, United States
    3. Shire, Lexington, United States
    4. University of California San Diego, La Jolla, United States 
      18:08-18:14 DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
    L.C. De Vries1, 2, M.E. Wildenberg1, 2, R.A. Willemze1, 2, H.P. van Hamersveld1, O. Welting1, C. Verseijden1, B. Strobl3, M. Mueller3, G.R. D'Haens2, W.J. De Jonge1
    1. Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands
    2. Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands
    3. University of Veterinary Medicine, Institute of Animal Breeding and Genetics, Vienna, Austria